Company History
1995 Exact Sciences founded
February 2001 Exact Sciences Initial Public Offering
March 2008 American Cancer Society includes sDNA testing in colorectal cancer screening guidelines
March 2009 American College of Gastroenterology includes sDNA testing in its colorectal cancer screening guidelines
April 2009 Kevin Conroy appointed President and Chief Executive Officer, Maneesh Arora appointed Chief Financial Officer
August 4, 2009 Graham Lidgard, PhD appointed Chief Scientific Officer
April 19, 2010 Exact Sciences raises $17.6 million in common stock offering
July 28, 2010 Poster presented at American Association for Clinical Chemistry (AACC) shows Exact Sciences methylation detection achieves 100% sensitivity and specificity in colorectal cancer tissue.
October 28, 2010 Results of Exact Sciences validation study released at American Association for Cancer Research (AACR) meeting in Philadelphia
November 10, 2010 Exact Sciences raises $64.7 million in common stock offering
July 2011 Exact Sciences begins enrollment for the DeeP-C Study, the company’s pivotal clinical trial for colon cancer
November 11, 2011 Exact Sciences presents data from a second validation study at the Association for Molecular Pathology annual meeting in Dallas, Texas
December 9, 2011 Exact Sciences raises $27.1 million in common stock offering
August 8, 2012 Exact Sciences raises $50.2 million in common stock offering
October 18, 2012 Poster presented at American Association for Cancer Research (AACR) Frontiers in Cancer Prevention meeting in Anaheim, California shows Exact Sciences, at a nominal specificity of 90%, achieves sensitivity of 98% in the detection of colorectal cancer and 83% in the detection of high-grade dysplasia, the majority of which progress to cancer
November 15, 2012 Exact Sciences completes enrollment of DeeP-C clinical trial, the largest privately funded study of its kind for colorectal cancer screening, enrolling more than 12,700 subjects
December 7, 2012 Exact Sciences submits to the U.S. Food and Drug Administration the first module of the premarket approval application for its stool DNA colorectal cancer screening test
April 18, 2013 Exact Sciences announces DeeP-C clinical trial preliminary top-line results
March 19, 2014 Results from the DeeP-C pivotal clinical study are published online in the New England Journal of Medicine
March 27, 2014 The U.S. Food and Drug Administration's (FDA) Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee determines by a unanimous vote of 10 to zero that Exact Sciences demonstrated safety, effectiveness and a favorable risk benefit profile of Cologuard ®, the company's stool-based DNA (sDNA), non-invasive colorectal cancer screening test
April 3, 2014 Results from the DeeP-C study are published in the New England Journal of Medicine’s April 2014 print issue
August 11, 2014 The U.S. Food and Drug Administration (FDA) approves Cologuard. Exact Sciences also receives a proposed coverage memorandum from the Centers for Medicare and Medicaid Services (CMS). Cologuard is the first product to take part in the joint FDA and CMS parallel review pilot program in which both agencies simultaneously review medical devices
October 9, 2014 The Centers for Medicare & Medicaid Services (CMS) issues its final National Coverage Determination (NCD) for Cologuard, making it the first and only Food and Drug Administration (FDA) approved stool DNA test for the detection of colorectal cancer and precancer covered by Medicare
November 6, 2014 The American Cancer Society (ACS) guidelines include Cologuard in a recommended list of screening options for colorectal cancer
February 6, 2015 Exact Sciences Corp. and Mayo Clinic announce a five-year extension and expansion of their collaboration, broadening their efforts to develop screening, surveillance and diagnostic tests beyond colorectal cancer to address other diseases within the gastrointestinal tract
June 15, 2016 United States Preventive Services Task Force (USPSTF) includes Cologuard in its final colorectal cancer screening recommendations on equal standing among the other included screening tests.
October 3, 2016 Cologuard included in the 2017 Healthcare Effectiveness Data and Information Set (HEDIS) quality measures for colorectal cancer screening. More than 90 percent of America's health plans measure quality based on HEDIS.